Following 110 years of neglect, an official day for Chagas disease is declared 24/05/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 24 May 2019 The delegates at the World Health Assembly (WHA) have today approved the creation of a World Chagas Day. People affected by Chagas worldwide celebrate this important step in fighting for recognition of this neglected disease. Image Credits: DNDi. Continue reading -> Drug Price Transparency: 10 Countries Back World Health Assembly Resolution 30/04/2019 Elaine Ruth Fletcher Ten countries, including five European Union (EU) member states, have now lined up in support of a landmark resolution to increase transparency of drug prices globally, which is expected to be a key focus of deliberations by WHO member states as they convene for the 72nd World Health Assembly (WHA), May 20-28 in Geneva. Image […] Continue reading -> DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 11/04/2019 Elaine Ruth Fletcher A diverse group of civil society, industry and government representatives convened today at the WHO-led 2nd Fair Pricing Forum in Johannesburg, South Africa, in the quest for new solutions that can unlock people’s access to desperately needed drugs at more affordable prices. Image Credits: Allison Colbert, Yannis Natsis. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Drug Price Transparency: 10 Countries Back World Health Assembly Resolution 30/04/2019 Elaine Ruth Fletcher Ten countries, including five European Union (EU) member states, have now lined up in support of a landmark resolution to increase transparency of drug prices globally, which is expected to be a key focus of deliberations by WHO member states as they convene for the 72nd World Health Assembly (WHA), May 20-28 in Geneva. Image […] Continue reading -> DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 11/04/2019 Elaine Ruth Fletcher A diverse group of civil society, industry and government representatives convened today at the WHO-led 2nd Fair Pricing Forum in Johannesburg, South Africa, in the quest for new solutions that can unlock people’s access to desperately needed drugs at more affordable prices. Image Credits: Allison Colbert, Yannis Natsis. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi). Image Credits: […] Continue reading -> DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 11/04/2019 Elaine Ruth Fletcher A diverse group of civil society, industry and government representatives convened today at the WHO-led 2nd Fair Pricing Forum in Johannesburg, South Africa, in the quest for new solutions that can unlock people’s access to desperately needed drugs at more affordable prices. Image Credits: Allison Colbert, Yannis Natsis. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 11/04/2019 Elaine Ruth Fletcher A diverse group of civil society, industry and government representatives convened today at the WHO-led 2nd Fair Pricing Forum in Johannesburg, South Africa, in the quest for new solutions that can unlock people’s access to desperately needed drugs at more affordable prices. Image Credits: Allison Colbert, Yannis Natsis. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 11/04/2019 Elaine Ruth Fletcher A diverse group of civil society, industry and government representatives convened today at the WHO-led 2nd Fair Pricing Forum in Johannesburg, South Africa, in the quest for new solutions that can unlock people’s access to desperately needed drugs at more affordable prices. Image Credits: Allison Colbert, Yannis Natsis. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts